a Medicine, Weill Cornell Medical Center , Division of General Internal Medicine , New York , NY , USA.
b Transplantation-Oncology Infectious Diseases Program, Medical Mycology Research Laboratory, Medicine, Pediatrics, and Microbiology & Immunology Weill Cornell Medical Center , Henry Schueler Foundation Scholar, Sharpe Family Foundation Scholar in Pediatric Infectious Diseases , New York , NY , USA.
Expert Opin Investig Drugs. 2017 Jul;26(7):825-831. doi: 10.1080/13543784.2017.1341488.
The widespread implementation of immunosuppressants, immunomodulators, hematopoietic stem cell transplantation and solid organ transplantation in clinical practice has led to an expanding population of patients who are at risk for invasive candidiasis, which is the most common form of fungal disease among hospitalized patients in the developed world. The emergence of drug-resistant Candida spp. has added to the morbidity associated with invasive candidiasis and novel therapeutic strategies are urgently needed. Areas covered: In this paper, we explore investigational agents for the treatment of invasive candidiasis, with particular attention paid to compounds that have recently entered phase I or phase II clinical trials. Expert opinion: The antifungal drug development pipeline has been severely limited due to regulatory hurdles and a systemic lack of investment in novel compounds. However, several promising drug development strategies have recently emerged, including chemical screens involving Pathogen Box compounds, combination antifungal therapy, and repurposing of existing agents that were initially developed to treat other conditions, all of which have the potential to redefine the treatment of invasive candidiasis.
免疫抑制剂、免疫调节剂、造血干细胞移植和实体器官移植在临床实践中的广泛应用，导致了侵袭性念珠菌病风险人群的扩大，这是发达国家住院患者中最常见的真菌感染形式。耐药念珠菌的出现增加了侵袭性念珠菌病的发病率，迫切需要新的治疗策略。
在本文中，我们探讨了治疗侵袭性念珠菌病的研究药物，特别关注最近进入 I 期或 II 期临床试验的化合物。
由于监管障碍和系统缺乏对新型化合物的投资，抗真菌药物的研发管道受到严重限制。然而，最近出现了几种有前途的药物研发策略，包括涉及病原体盒化合物的化学筛选、联合抗真菌治疗以及重新利用最初开发用于治疗其他疾病的现有药物，所有这些都有可能重新定义侵袭性念珠菌病的治疗方法。
